全部

1·The reduced nigrostriatal uptake seen on imaging in 10 of the 21 patients indicated dopamine transporter dysfunction.

21例患者中有10例患者影像学显示黑质纹状体摄取减少，表明存在多巴胺转运体功能障碍。

2·Two other studies found no elevation of transporter levels, though one found a decrease in dopamine transporter levels in a different brain region.

另外的两项研究没有发现该蛋白水平的升高，一项则发现在不同脑部区域该蛋白水平的降低。

3·The aim of this study was to determine the effect of brain aging and the role of ASN and NAC peptide on striatal dopamine transporter (DAT) function.

此研究的目的拟确定脑老化的影响和asn、NAC肽对纹状体的多巴胺转运体(DAT)功能的作用。

4·Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study.

连续多巴胺转运蛋白显像与特发性快动眼睡眠行为障碍患者的黑质纹状体功能：一项前瞻性研究。

5·Three hours after receiving an injection of the radiopharmaceutical 123i-fp-cit, patients underwent single-photon emission tomography (SPECT) scanning to assess baseline dopamine transporter function.

在接受放射性药物123i - FP - CIT注射3小时后，患者进行了单光子发射断层扫描(SPECT)成像评估基线多巴胺转运体功能。